{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:56:13Z","timestamp":1793361373822,"version":"4.5.0"},"reference-count":52,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China","award":["81970238"],"award-info":[{"award-number":["81970238"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China","award":["82170406"],"award-info":[{"award-number":["82170406"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China","award":["112336"],"award-info":[{"award-number":["112336"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China","award":["IEC\\NSFC\\201094"],"award-info":[{"award-number":["IEC\\NSFC\\201094"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Alzheimer\u2019s Research UK South West","award":["81970238"],"award-info":[{"award-number":["81970238"]}],"id":[{"id":"https:\/\/ror.org\/02ymzm013","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Alzheimer\u2019s Research UK South West","award":["82170406"],"award-info":[{"award-number":["82170406"]}],"id":[{"id":"https:\/\/ror.org\/02ymzm013","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Alzheimer\u2019s Research UK South West","award":["112336"],"award-info":[{"award-number":["112336"]}],"id":[{"id":"https:\/\/ror.org\/02ymzm013","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Alzheimer\u2019s Research UK South West","award":["IEC\\NSFC\\201094"],"award-info":[{"award-number":["IEC\\NSFC\\201094"]}],"id":[{"id":"https:\/\/ror.org\/02ymzm013","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The Royal Society UK","award":["81970238"],"award-info":[{"award-number":["81970238"]}],"id":[{"id":"https:\/\/ror.org\/03wnrjx87","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The Royal Society UK","award":["82170406"],"award-info":[{"award-number":["82170406"]}],"id":[{"id":"https:\/\/ror.org\/03wnrjx87","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The Royal Society UK","award":["112336"],"award-info":[{"award-number":["112336"]}],"id":[{"id":"https:\/\/ror.org\/03wnrjx87","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The Royal Society UK","award":["IEC\\NSFC\\201094"],"award-info":[{"award-number":["IEC\\NSFC\\201094"]}],"id":[{"id":"https:\/\/ror.org\/03wnrjx87","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Hypertension is a known risk factor for cognition-related pathologies including dementia. The National Institute of Health and Care Excellence (NICE) guidelines recommend angiotensin (Ang) II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) as a first-line treatment for hypertension. Although both ARBs and ACEIs show neuroprotective effects, ACEIs show contradictory side effects; therefore, ARBs may be a more viable option. However, trials assessing the effects of ARBs on cognition are scarce and conflicting. Therefore, the aim of this review is to conduct a systematic review and synthesise data on the influence of ARBs on cognition and dementia prevention. Five databases were searched from 1992\u20132022 to produce 13 randomised controlled trials (RCTs) involving 26,907 patients that compared associations of ARBs against placebos or other antihypertensives on cognition or probable dementia with a minimum duration of 3 months. ARBs showed greater cognitive benefits when compared to hydrochlorothiazide (HCTZ), beta blockers (BB), and ACEIs. Our findings showed that although ARBs are superior to some antihypertensives such as ACEIs, thiazide and beta blockers, they made no difference in comparison to the placebo in all but one sample of patients. The positive effects on cognitive performances are equal to calcium channel blockers (CCBs) and lower than statin. The neuroprotective effects of ARBs are also more beneficial when ARBs are taken at the same time as a statin. Due to these inconsistencies, robust conclusions cannot be made. Future trials are warranted and, if successful, could have positive economic implications and consequently improve quality of life.<\/jats:p>","DOI":"10.3390\/pharmaceutics14102123","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T01:21:07Z","timestamp":1665364867000},"page":"2123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Angiotensin II Receptor Blockers in the Management of Hypertension in Preventing Cognitive Impairment and Dementia\u2014A Systematic Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9825-9835","authenticated-orcid":false,"given":"Elvira","family":"D\u2019Silva","sequence":"first","affiliation":[{"name":"Hatherly Laboratories, Institute of Biomedical and Clinical Sciences, Medical School, Faculty of Health and Life Sciences, Streatham Campus, University of Exeter, Exeter EX4 4PS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1030-4668","authenticated-orcid":false,"given":"Nur Farah","family":"Meor Azlan","sequence":"additional","affiliation":[{"name":"Hatherly Laboratories, Institute of Biomedical and Clinical Sciences, Medical School, Faculty of Health and Life Sciences, Streatham Campus, University of Exeter, Exeter EX4 4PS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8683-509X","authenticated-orcid":false,"given":"Jinwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hatherly Laboratories, Institute of Biomedical and Clinical Sciences, Medical School, Faculty of Health and Life Sciences, Streatham Campus, University of Exeter, Exeter EX4 4PS, UK"},{"name":"School of Medicine, Xiamen Cardiovascular Hospital of Xiamen University, Xiamen University, Xiang\u2019an Nan Lu, Xiamen 361102, China"},{"name":"State Key Laboratory of Bioorganic & Natural Products Chemistry, Research Center of Chemical Kinomics, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, # 345 Lingling Road, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"ref_1","unstructured":"(2022, February 22). World Alzheimer Report 2021: Journey through the Diagnosis of Dementia. ADI Commissioned McGill University. Available online: https:\/\/www.alzint.org\/resource\/world-alzheimer-report-2021\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7748\/ns.29.37.37.e9405","article-title":"Dementia: Definitions and types","volume":"29","author":"Dening","year":"2015","journal-title":"Nurs. Stand."},{"key":"ref_3","unstructured":"(2022, February 22). Dementia\u2014WHO, by World Health Organization. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1161\/STROKEAHA.116.012658","article-title":"Blood Pressure and Risk of Vascular Dementia: Evidence from a Primary Care Registry and a Cohort Study of Transient Ischemic Attack and Stroke","volume":"47","author":"Emdin","year":"2016","journal-title":"Stroke"},{"key":"ref_6","unstructured":"(2022, February 22). Hypertension in Adults: Diagnosis and Management, by NICE Guideline. Available online: https:\/\/www.nice.org.uk\/guidance\/ng136\/chapter\/Recommendations#startingantihypertensive-drug-treatment."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","article-title":"Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies","volume":"94","author":"Patel","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/ajh\/hpu197","article-title":"Neuroprotective effects of angiotensin receptor blockers","volume":"28","author":"Villapol","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"b5465","DOI":"10.1136\/bmj.b5465","article-title":"Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis","volume":"340","author":"Li","year":"2010","journal-title":"BMJ"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3233\/JAD-2011-110347","article-title":"Associations of antihypertensive treatments with Alzheimer\u2019s disease, vascular dementia, and other dementias","volume":"26","author":"Davies","year":"2011","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jamda.2020.12.019","article-title":"Antihypertensive Medication Classes and the Risk of Dementia: A Systematic Review and Network Meta-Analysis","volume":"22","author":"Abdulrahman","year":"2021","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/HJH.0b013e3283603f53","article-title":"Antihypertensive classes, cognitive decline and incidence of dementia: A network meta-analysis","volume":"31","author":"Tropeano","year":"2013","journal-title":"J. Hypertens."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/14656566.2017.1333599","article-title":"Treatment options and considerations for hypertensive patients to prevent dementia","volume":"18","author":"Hernandorena","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1474-4422(19)30393-X","article-title":"Antihypertensive medications and risk for incident dementia and Alzheimer\u2019s disease: A meta-analysis of individual participant data from prospective cohort studies","volume":"19","author":"Ding","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1212\/WNL.0000000000008732","article-title":"Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis","volume":"94","author":"Peters","year":"2020","journal-title":"Neurology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"841","DOI":"10.14336\/AD.2020.1111","article-title":"Effects of Antihypertensive Drugs on Cognitive Function in Elderly Patients with Hypertension: A Review","volume":"12","author":"Yang","year":"2021","journal-title":"Aging Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/HJH.0b013e3283371355","article-title":"More indirect evidence of potential neuroprotective benefits of angiotensin receptor blockers","volume":"28","author":"Anderson","year":"2010","journal-title":"J. Hypertens."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.phrs.2017.06.017","article-title":"Beneficial effects of Angiotensin II receptor blockers in brain disorders","volume":"125","author":"Saavedra","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10571-015-0327-y","article-title":"Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer\u2019s Disease","volume":"36","author":"Saavedra","year":"2016","journal-title":"Cell Mol. Neurobiol."},{"key":"ref_20","unstructured":"(2022, February 22). Available online: http:\/\/www.prismastatement.org\/PRISMAStatement\/CitingAndUsingPRISMA.aspx."},{"key":"ref_21","unstructured":"(2022, February 22). RoB 2: A Revised Cochrane Risk-of-Bias Tool for Randomized Trials, by Cochrane Bias. Available online: https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0895-7061(99)00156-9","article-title":"Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients","volume":"12","author":"Tedesco","year":"1999","journal-title":"Am. J. Hypertens."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.jhh.1001613","article-title":"Influence of losartan and atenolol on memory function in very elderly hypertensive patients","volume":"17","author":"Fogari","year":"2003","journal-title":"J. Hum. Hypertens."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00228-003-0717-9","article-title":"Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension","volume":"59","author":"Fogari","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","article-title":"Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: Principal results of a prospective randomized controlled study (MOSES)","volume":"36","author":"Schrader","year":"2005","journal-title":"Stroke"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1474-4422(08)70198-4","article-title":"Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: A double-blind, active and placebo-controlled study","volume":"7","author":"Diener","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/01.wnl.0000311447.85948.78","article-title":"Candesartan and cognitive decline in older patients with hypertension: A substudy of the SCOPE trial","volume":"70","author":"Saxby","year":"2008","journal-title":"Neurology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00392-008-0719-9","article-title":"ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting","volume":"98","author":"Flesch","year":"2009","journal-title":"Clin. Res. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1447-0594.2011.00746.x","article-title":"Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer\u2019s disease","volume":"12","author":"Kume","year":"2012","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/STROKEAHA.113.001022","article-title":"Effects of candesartan in acute stroke on cognitive function and quality of life: Results from the Scandinavian Candesartan Acute Stroke Trial","volume":"44","author":"Hornslien","year":"2013","journal-title":"Stroke"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41440-018-0165-7","article-title":"Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: A randomized, double-blind and placebo-controlled clinical trial","volume":"42","author":"Zhang","year":"2019","journal-title":"Hypertens. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e2012252","DOI":"10.1001\/jamanetworkopen.2020.12252","article-title":"Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment: A Randomized Clinical Trial","volume":"3","author":"Hajjar","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fnagi.2020.00154","article-title":"Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype","volume":"12","author":"Hu","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1474-4422(21)00263-5","article-title":"Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer\u2019s disease (the RADAR trial): A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"20","author":"Kehoe","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_35","unstructured":"(2022, February 22). CASP\u2014Critical Appraisal Skills Programme. Available online: https:\/\/casp-uk.net\/casp-tools-checklists\/."},{"key":"ref_36","unstructured":"(2022, February 22). The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. World Alzheimer Report 2015. Available online: https:\/\/www.alzint.org\/resource\/world-alzheimer-report-2015\/."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/9781119536604.ch8","article-title":"Assessing risk of bias due to missing results in a synthesis","volume":"Volume 13","author":"Higgins","year":"2019","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0361-9230(93)90036-B","article-title":"Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat","volume":"30","author":"Li","year":"1993","journal-title":"Brain Res. Bull."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00001756-199208000-00013","article-title":"Angiotensin AT2 receptors regulate cerebral blood flow in rats","volume":"3","author":"Stromberg","year":"1992","journal-title":"Neuroreport"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"20233","DOI":"10.1038\/s41598-020-75450-6","article-title":"Stroke promotes the development of brain atrophy and delayed cell death in hypertensive rats","volume":"10","author":"Sayed","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1258\/jrsm.2008.08k033","article-title":"Why animal studies are often poor predictors of human reactions to exposure","volume":"102","author":"Bracken","year":"2009","journal-title":"J. R. Soc. Med."},{"key":"ref_42","unstructured":"Higgins, J., and Green, S. (2011). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0, John Wiley & Sons, Ltd."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S2213-2600(19)30471-0","article-title":"Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: A randomised, double-blind, controlled, parallel-group, phase 2b trial","volume":"8","author":"Smith","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/bmj.332.7547.969","article-title":"Reporting attrition in randomised controlled trials","volume":"332","author":"Dumville","year":"2006","journal-title":"BMJ"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bcp.12511","article-title":"Angiotensin receptor blockers and risk of dementia: Cohort study in UK Clinical Practice Research Datalink","volume":"79","author":"Goh","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3233\/JAD-180943","article-title":"Observational Study of Brain Atrophy and Cognitive Decline Comparing a Sample of Community-Dwelling People Taking Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Over Time","volume":"68","author":"Moran","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1097\/HJH.0b013e328301a280","article-title":"Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: Primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study","volume":"26","author":"Hanon","year":"2008","journal-title":"J. Hypertens."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.18203\/2319-2003.ijbcp20202937","article-title":"Effect of telmisartan on hypertensive dementia patients: An observational study","volume":"9","author":"Keshri","year":"2020","journal-title":"Int. J. Basic Clin. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13195-017-0255-9","article-title":"Memory is preserved in older adults taking AT1 receptor blockers","volume":"9","author":"Ho","year":"2017","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(07)70291-0","article-title":"Lifetime risk of stroke and dementia: Current concepts, and estimates from the Framingham Study","volume":"6","author":"Seshadri","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/gps.4198","article-title":"The main cost drivers in dementia: A systematic review","volume":"30","author":"Schaller","year":"2015","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_52","unstructured":"(2022, February 22). How Much Does Dementia Care Cost? by Alzheimer\u2019s Society. Available online: https:\/\/www.alzheimers.org.uk\/blog\/how-much-does-dementia-care-cost."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/10\/2123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:47:23Z","timestamp":1760143643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/10\/2123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["pharmaceutics14102123"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14102123","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]}}}